Streetbeat News

BPTH

Bio-Path Holdings, Inc.

https://www.biopathholdings.com

Industry

Biotechnology

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Open

0.90

Mkt cap

3.3M

Volume

43K

High

0.92

P/E Ratio

-0.06

52-wk high

12.40

Low

0.87

Div yield

N/A

52-wk low

0.80

Healthcare stocks showed significant movement in Wednesday's after-market session. Gainers included Modular Medical (MODD), Atreca (BCEL), Pieris Pharmaceuticals (PIRS), DarioHealth (DRIO), PAVmed (PAVM), and AIM ImmunoTech (AIM). Losers included Vivos Therapeutics (VVOS), Alpha Tau Medical (DRTS), Bio-Path Hldgs (BPTH), Novo Integrated Sciences (NVOS), Alaunos Therapeutics (TCRT), and MSP Recovery (LIFW).

Portfolio Pulse from Benzinga Insights

August 16, 2023 | 9:32 pm

Bio-Path Holdings reported Q2 losses of $(0.53) per share, missing the analyst consensus estimate of $(0.44) by 20.45 percent. This represents a 26.19 percent decrease over losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 11:15 am

Bio-Path Holdings reported Q2 losses of $(0.42) per share, beating the analyst consensus estimate of $(0.44) by 4.55%. The company had cash of $3.4M as of June 30. The EPS is unchanged from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 11:01 am

Bio-Path Holdings (NASDAQ:BPTH) is set to release its latest quarterly earnings report on August 15, 2023. Analysts estimate an earnings per share (EPS) of $-0.44. The company's past performance shows a trend of missing EPS estimates and subsequent drops in share price. The stock is currently trading at $0.4, down 89.81% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 4:01 pm

U.S. stocks were mixed with Dow trading down 0.05% and NASDAQ rising 0.05%. Kellogg Company (NYSE:K) reported better-than-expected earnings for its second quarter with organic sales growth of 7.1% YoY to $4.14 billion. Upwork Inc. (NASDAQ:UPWK), Vital Farms, Inc. (NASDAQ:VITL), and Traeger, Inc. (NYSE:COOK) saw their shares rise after posting strong quarterly results. However, Aravive, Inc. (NASDAQ:ARAV), Bio-Path Holdings, Inc. (NASDAQ:BPTH), and Vicarious Surgical Inc. (NYSE:RBOT) saw their shares drop due to various reasons including unsuccessful trials and public offering pricing.

Portfolio Pulse from Lisa Levin

August 04, 2023 | 2:14 pm

During Thursday's session, 92 stocks hit new 52-week lows. Pfizer was the biggest company on a market cap basis to set a new 52-week low. BitNile Metaverse was the smallest firm by market cap to set a new 52-week low. Aravive made the largest move down on the session, with shares plummeting 71.75% to reach its 52-week low. Senstar Tech saw the biggest bounce back on, as shares traded up 0.0% to rebound after it hit its new 52-week low.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 2:12 pm

Bio Path Holdings Inc (BPTH) shares have dropped by 45.95% after the company priced a 3.5 million unit offering at $0.60 per unit. The offering, which includes common stock purchase warrants, is expected to generate around $2.1 million in gross proceeds and close around August 7. The proceeds will be used for working capital and general corporate purposes.

Portfolio Pulse from Henry Khederian

August 04, 2023 | 2:06 pm

Bio-Path Holdings has priced a 3.5 million unit offering at $0.60 per unit, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:59 pm

Numerous stocks experienced significant price changes in Thursday's mid-day session. Companies that posted strong quarterly results, such as Traeger, Inc. (COOK), Upwork Inc. (UPWK), and The Clorox Company (CLX), saw their shares rise. Conversely, companies that reported worse-than-expected results or issued below-consensus outlooks, such as DXC Technology Company (DXC), Expedia Group, Inc. (EXPE), and Cummins Inc. (CMI), saw their shares fall.

Portfolio Pulse from Lisa Levin

August 04, 2023 | 1:56 pm

U.S. stocks were mixed with the Nasdaq Composite slightly higher. The ISM services PMI declined to 52.7 in July from 53.9 in June. Upwork Inc., Vital Farms, Inc., and Traeger, Inc. saw their shares rise after posting strong quarterly results. Aravive, Inc., Bio-Path Holdings, Inc., and Vicarious Surgical Inc. saw their shares drop due to disappointing news.

Portfolio Pulse from Lisa Levin

August 04, 2023 | 1:52 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.